Compare CCO & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCO | URGN |
|---|---|---|
| Founded | 1995 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2005 | 2016 |
| Metric | CCO | URGN |
|---|---|---|
| Price | $2.40 | $29.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $2.12 | ★ $29.29 |
| AVG Volume (30 Days) | ★ 7.3M | 595.6K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 110.81 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,604,140,000.00 | $1,128,000.00 |
| Revenue This Year | $5.35 | $129.09 |
| Revenue Next Year | $4.26 | $70.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 6.57 | N/A |
| 52 Week Low | $1.00 | $12.62 |
| 52 Week High | $2.43 | $32.37 |
| Indicator | CCO | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 49.35 | 61.76 |
| Support Level | $2.37 | $26.67 |
| Resistance Level | $2.41 | $30.34 |
| Average True Range (ATR) | 0.01 | 1.54 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 25.00 | 72.75 |
Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.